Welcome to our dedicated page for Invizyne Technologies SEC filings (Ticker: IZTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Invizyne Technologies’ enzyme-dense disclosures can feel like running a lab experiment without the protocol. Patent claims for cell-free “exozymes”, grant-tied milestones, and multi-layer R&D expenses hide in footnotes across the annual report. If you have ever searched “Invizyne Technologies SEC filings explained simply” or wondered where to track “Invizyne Technologies insider trading Form 4 transactions,” you know the challenge.
Stock Titan’s AI solves it. Our engine reads every Invizyne Technologies quarterly earnings report 10-Q filing, each 8-K material events explained, and the full annual report 10-K simplified in seconds—highlighting cash-burn trends, new patent issuances, and sustainability metrics. Need “Invizyne Technologies Form 4 insider transactions real-time”? You’ll get instant alerts the moment an executive files. Prefer narrative? Our AI-powered summaries translate biochemical jargon into plain English, showing how enzyme pathway efficiency or government grant milestones affect the bottom line.
Whether you’re analyzing “Invizyne Technologies earnings report filing analysis,” comparing segment spend, or drilling into “Invizyne Technologies proxy statement executive compensation,” the complete archive is here—10-Q, 10-K, 8-K, S-1, DEF 14A, and more. Monitor “Invizyne Technologies executive stock transactions Form 4,” follow R&D capitalization trends, or export data for modeling. Real-time updates from EDGAR, expert commentary, and AI summaries ensure you never miss the next breakthrough—or the next dilution risk—hidden inside the fine print.
Exozymes (Nasdaq: EXOZ) filed an 8-K disclosing entry into the NSF-funded Meta-PURE initiative under the CFIRE program. The three-year cooperative agreement—total award $9.2 million—will deliver about $3 million to Exozymes beginning 1 July 2025.
As the project’s key industrial partner, Exozymes will build a cell-free ATP-generating “power plant” and a production module for high-value fragrance compound santalene. These plug-and-play modules aim to speed reaction times and boost yields across multiple synthetic-biology applications. No additional financial statements, guidance, or dilution were reported.
Invizyne Technologies Inc. ("IZTC") has filed Amendment No. 1 to its definitive proxy statement (Form DEFR14A) to correct the proxy card for Proposal 1, the election of directors. The updated card now offers shareholders the standard choices of "For All," "Withhold All," or "For All Except," and explains how to withhold authority for specific nominees.
The company notes that proxy materials have not yet been distributed, so investors will receive only the corrected version, avoiding the need for multiple or color-coded cards. No other proposals, financial metrics, or strategic items were affected by this administrative update.
eXoZymes Inc. (symbol: IZTC) has filed its Definitive Proxy Statement (Schedule 14A) for the 2025 Annual Meeting of Shareholders. The meeting will be held virtually on July 25, 2025 at 1:00 p.m. Pacific Time via www.virtualshareholdermeeting.com/EXOZ2025; in-person attendance is not permitted. Shareholders of record at the close of business on June 9, 2025 are entitled to vote, and proxy materials will be mailed or otherwise made available on or about June 20, 2025.
The proxy lists five voting items:
- Proposal 1: Election of six directors to serve until the 2026 AGM.
- Proposal 2: Non-binding advisory vote on 2025 executive compensation (say-on-pay).
- Proposal 3: Advisory vote on the frequency of future say-on-pay resolutions, with the Board favoring a three-year cycle.
- Proposal 4: Approval of the new 2025 Performance Equity Plan.
- Proposal 5: Ratification of RBSM LLP as independent registered public accounting firm for FY 2025.
The Board of Directors recommends a “FOR” vote on all proposals, including the adoption of the equity plan and three-year say-on-pay frequency. No additional matters are expected, but any other proper business may be transacted.
The filing is routine in nature, with no financial performance data, mergers, or capital-raising activities disclosed. Key governance items include detailed information on board structure, risk oversight, director independence, compensation philosophy, and a clawback policy.
eXoZymes Inc. (Nasdaq: EXOZ) filed a Form 8-K on June 17, 2025 disclosing changes to the compensation package of Chief Executive Officer Michael Heltzen under Item 5.02.
• Base salary: increased to an annualized $450,000.
• Equity incentive: option grant covering 235,817 common shares at an exercise price of $12.40 per share. Vesting will occur in equal quarterly installments over four years beginning July 1 2025 and the options expire June 29 2032.
• Cash bonus: one-time payment of $250,000.
The filing contains no additional operational or financial data. The compensation committee approved the adjustments, indicating a focus on talent retention and long-term alignment through equity, though the grant introduces incremental dilution and higher cash outflow.
No other items were reported; the only exhibit referenced is the Inline XBRL cover page (Exhibit 104).
Form 4 highlights: Exozymes Inc. (ticker EXOZ) filed a Form 4 disclosing that Chief Executive Officer Michael Heltzen received a new equity award on 06/17/2025.
- Security granted: Non-qualified stock options covering 235,817 shares of common stock.
- Exercise price: $12.40 per share.
- Vesting schedule: Options vest quarterly over four years, beginning 07/01/2025, and fully vest by mid-2029.
- Expiration: 06/29/2032.
- Post-grant holdings: 235,817 derivative securities beneficially owned (no direct share ownership reported, no shares sold).
The filing indicates a routine compensation grant rather than an open-market purchase or sale. While it does not immediately alter cash flow or earnings, it increases potential future share count and reinforces long-term alignment between the CEO and shareholders. No other transactions, amendments, or 10b5-1 plans were disclosed.
FAQ
What is the current stock price of Invizyne Technologies (IZTC)?
What is the market cap of Invizyne Technologies (IZTC)?
What is the core technology behind Invizyne Technologies Inc.?
How does Invizyne differentiate itself from traditional chemical manufacturing?
Which industries can benefit from Invizyne's biomanufacturing solutions?
What role does AI play in the company’s technology?
How does the company address scalability challenges in chemical production?
What makes Invizyne's platform a compelling alternative to traditional synthetic biology?
How is Invizyne positioned within the competitive landscape of biomanufacturing?
Are there any unique terms or concepts associated with Invizyne's technology?
